-
06:43:23 AM

AFMD - Affimed N.V.

04/12/21 6:30 AM
Nasdaq : AFMD
Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I
AFM24 induces strong tumor cell killing independent of KRAS mutations AFM24, in combination with adoptive NK cells, leads to dose-dependent tumor regression Heidelberg, Germany, April 12, 2021 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back
RHEA-AI
neutral
04/09/21 5:59 AM
Nasdaq : AFMD
Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100% There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease
RHEA-AI
very positive
03/31/21 6:30 AM
Nasdaq : AFMD
Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors
Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 - Affimed N.V. (NASDAQ: AFMD), a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) cleared an investigational new drug
RHEA-AI
neutral